 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
10 News |  |
- Interleukin 6 inhibitor / Evotec, Interprotein Corp
Cytokine Profiling Reveals Distinctive Immune Responses in Dengue, Zika, Chikungunya and Mayaro Virus Infections (Convention Center - Hall I-1 (1st Floor); In-Person-Only) - Oct 11, 2024 - Abstract #ASTMH2024ASTMH_2782;
showed a similar pattern, with DENV and ZIKV patients expressing the highest levels. Understanding the distinct immunological signatures of these arboviruses is crucial for effective diagnostic and therapeutic approaches in high-risk regions.
- || Interleukin 6 inhibitor / Evotec, Interprotein Corp
Biomarker, Retrospective data, Review, Journal: Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis. (Pubmed Central) - Dec 17, 2023
Understanding the distinct immunological signatures of these arboviruses is crucial for effective diagnostic and therapeutic approaches in high-risk regions. Novel biomarkers, including IL-6, uNGAL and copeptin, can probably improve prognostication of patients with decompensated cirrhosis compared with MELD alone.
- | Interleukin 6 inhibitor / Evotec, Interprotein Corp
Journal, Stroma: Impact of soluble tumor necrosis factor-related apoptosis-inducing ligand released by engineered adipose mesenchymal stromal cells on white blood cells. (Pubmed Central) - Apr 4, 2023
Novel biomarkers, including IL-6, uNGAL and copeptin, can probably improve prognostication of patients with decompensated cirrhosis compared with MELD alone. In summary, this study demonstrates the immunological safety and thus the clinical feasibility of an anticancer approach based on AD-MSC expressing the proapoptotic molecule sTRAIL.
- | Interleukin 6 inhibitor / Evotec, Interprotein Corp
Journal: Discovery of a Novel Small-Molecule Interleukin-6 Inhibitor through Virtual Screening Using Artificial Intelligence. (Pubmed Central) - Apr 13, 2022
Our screening compound demonstrated an inhibitory effect on IL-6 stimulus. These findings may serve as a basis for the further development of small-molecule IL-6 inhibitors.